---
title: Dr. Sonal Kumar — drug & device company payments (CMS Open Payments 2024)
license: CC0-1.0
source: CMS Open Payments PY2024 (Sunshine Act)
---

# Dr. Sonal Kumar — drug & device company payments (CMS Open Payments 2024)

CMS Open Payments PY2024 records for Dr. Sonal Kumar (Gastroenterology, NEW YORK, NY, NPI 1952523268): $304,180 total across 226 payments from drug and device companies. Split by relevance: $275,970 promotional (marketing), $28,210 royalty/ownership, $0 research/other. Largest payers: Novo Nordisk Inc ($98,394), Ipsen Biopharmaceuticals, Inc ($96,599), Gilead Sciences, Inc. ($50,215). Source: Sunshine Act. CC0.

## Claims

### Total 2024 industry payments to Dr. Sonal Kumar

**RECORDED.** In 2024, drug and device companies reported $304,180 in payments to Dr. Sonal Kumar (Gastroenterology, NEW YORK, NY) across 226 payments.

Source: CMS Open Payments PY2024 (Sunshine Act) — https://openpaymentsdata.cms.gov/
Falsifier: A RECORD of measured/reported events (occurred=true) from CMS Open Payments PY2024 (Sunshine Act); superseded when CMS Open Payments PY2024 (Sunshine Act) publishes its next release.

### Payment composition: promotional vs royalty vs other

**INTERPRETATION.** Of that, $275,970 is promotional (meals, speaking, travel, consulting — a company marketing its products), $28,210 is royalty/ownership (income for inventing or owning something, not a prescribing conflict), and $0 is research/grants/other.

Source: Atlas Commons grouping of CMS nature-of-payment codes by patient relevance — https://care-atlas.ryanjhunter.workers.dev/
Falsifier: occurred=FALSE (a framing, not an event) and adjudged=FALSE (an in-house reading, not an authority's verdict) — the LOWEST-warrant claim here. A flat representation would render this identically to the official facts; the four-status does not.

### Largest paying companies (in-house ranking over CMS records)

**DERIVED.** Largest paying companies: Novo Nordisk Inc ($98,394), Ipsen Biopharmaceuticals, Inc ($96,599), Gilead Sciences, Inc. ($50,215), INTERCEPT PHARMACEUTICALS, INC. ($40,559), Ipsen Pharma SAS ($22,422). The company names and per-payment amounts are CMS-recorded; the "largest" ranking and selection are an in-house aggregation, so adjudged=FALSE — CMS did not adjudge this ranking.

Source: Atlas Commons ranking over CMS Open Payments PY2024 by-company records — https://openpaymentsdata.cms.gov/
Falsifier: occurred=FALSE (a calculation, not an event) and adjudged=FALSE (a transparent in-house formula, not an authority's verdict — no external adjudicator). Reproduce it from its named inputs; falsified if the formula or inputs are wrong. Lower warrant than the adjudged figures above.

### What an Open Payments figure is — and is NOT

**INTERPRETATION.** A disclosed Open Payments amount is a publicly-reported financial relationship; it is not proof of wrongdoing and not evidence it changed patient care. It is not a rating of this physician.

Source: Sunshine Act transparency purpose; Atlas Commons L5 boundary — https://care-atlas.ryanjhunter.workers.dev/
Falsifier: occurred=FALSE (a framing, not an event) and adjudged=FALSE (an in-house reading, not an authority's verdict) — the LOWEST-warrant claim here. A flat representation would render this identically to the official facts; the four-status does not.

---

Every claim above carries a four-status warrant (RECORDED / MODELED / DERIVED / INTERPRETATION) and a named source you can re-fetch — this is a research object, not a flat fact. Structured: `https://care-atlas.ryanjhunter.workers.dev/payments/1952523268.jsonld`

## Data

### 2024 payment summary — Dr. Sonal Kumar

CMS Open Payments PY2024. Nature split (INTERPRETATION) is Atlas Commons grouping, not a CMS category.

| Category | Amount | Warrant |
| --- | --- | --- |
| Total payments | $304,180 | RECORDED |
| Promotional | $275,970 | INTERPRETATION |
| Royalty / ownership | $28,210 | INTERPRETATION |
| Research / other | $0 | INTERPRETATION |

### Largest paying companies

In-house ranking over CMS records (DERIVED). Company names and amounts are CMS-RECORDED.

| Company | Amount paid (2024) | Warrant |
| --- | --- | --- |
| Novo Nordisk Inc | $98,394 | DERIVED |
| Ipsen Biopharmaceuticals, Inc | $96,599 | DERIVED |
| Gilead Sciences, Inc. | $50,215 | DERIVED |
| INTERCEPT PHARMACEUTICALS, INC. | $40,559 | DERIVED |
| Ipsen Pharma SAS | $22,422 | DERIVED |

### Payments by CMS nature-of-payment code

CMS-reported nature codes (RECORDED).

| Nature | Code | Amount | Warrant |
| --- | --- | --- | --- |
| Speaking / services (non-CE) | 2 | $126,816 | RECORDED |
| Consulting fees | 1 | $99,423 | RECORDED |
| Travel & lodging | 7 | $32,196 | RECORDED |
| Long-term device/supply loan | 16 | $28,210 | RECORDED |
| Honoraria | 3 | $10,583 | RECORDED |
| Food & beverage | 6 | $6,952 | RECORDED |